39 results about "Endothelial dysfunction" patented technology

The application provides a thermoelectric hydrogel composite dressing for promoting repair of diabetic ulcers and loading of targeted modified exosomes and a preparation method, which comprises the following steps: preparing methacrylated hyaluronic acid; preparing polyether F127 diacrylate; co-incubating exosomes with palmitic acid grafted targeting peptides to prepare targeted modified exosomes; mixing the methacrylated hyaluronic acid, the polyether F127 diacrylate, a photosensitizer, the targeted modified exosomes and an electrolyte, and crosslinking under ultraviolet light to form a composite gel. The composite dressing is a novel composite dressing for thermoelectric stimulation and exosome treatment. On one hand, the dressing generates a wireless and passive electric field to simulate the endogenous electric field in the wound, promote directional migration of skin cells, accelerate reepithelialization and dermal formation; on the other hand, the dressing releases exosomes to precisely target blood vessels of a wound lesion, reverse endothelial dysfunction in a high-sugar environment and promote angiogenesis, and effectively solves the problems in repair and regeneration of diabetic ulcer wounds.

Provided is the use of a traditional Chinese medicine composition in preparation of a drug for preventing major adverse cardiac and cerebrovascular events after percutaneous coronary intervention and ameliorating myocardial injury and vascular endothelial dysfunction after percutaneous coronary intervention. The traditional Chinese medicine composition is composed of total salvianolic acid and total hawthorn triterpene acid.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

A pharmaceutical composition including a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting after onset of an infection in a human subject. In preferred embodiments, the pharmaceutical composition comprises a soluble guanylate cyclase stimulator or salt thereof, preferably vericiguat, for use in the treatment of a chronic vascular dysfunction associated with vascular constriction, endothelial dysfunction and / or hypo-perfusion.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

The invention discloses a method for extracting 7-hydroxy-8-O-beta-D-glucopyranoside-coumarin from apple peel, a compound extracted by the method and application of the compound. The invention belongs to the field of extraction and separation of natural products, and relates to a coumarin compound found in apple peel. The invention further provides a separation and identification method of the novel compound. Methanol extraction, ethyl acetate elution and a high performance liquid chromatograph are sequentially adopted for separation, purification and preparation. The structure of the compound is determined to be the compound found in apple peel for the first time by adopting nuclear magnetic identification of hydrogen spectrum and carbon spectrum. The compound has a protective effect on vascular endothelial dysfunction caused by hyperlipidemia, has no toxic effect on cells, and can be used as a raw material for drug development and pharmacological activity research.

The invention discloses an anti-human IGFBP7 monoclonal antibody and application thereof, and relates to the technical field of immunotherapy, in particular to the anti-human IGFBP7 monoclonal antibody aiming at an IGFBP7 target spot, after the anti-human IGFBP7 monoclonal antibody is adopted for treatment, the inflammation of a mouse is obviously relieved, the skin vascular system is recovered, and the anti-human IGFBP7 monoclonal antibody has a treatment effect on endothelial dysfunction and psoriasis.

A method for determining a risk of sepsis in a patient is disclosed. The method includes collecting an exhaled breath sample, determining a NO concentration in the exhaled breath sample; and determining a sepsis risk score correlated to the NO concentration, wherein the sepsis risk score is indicative of a risk of a patient having or developing sepsis. The method may further include determining an additional measurement of the patient's vital statistics including one or more of: end tidal CO2, respiratory rate, pulse rate, body temperature, cognitive assessment score, systolic blood pressure, diastolic blood pressure, or hemoglobin oxygen saturation level, and further determining the sepsis risk score based on the additional measurement.

Subject of the invention are DPP3 binders for use in therapy or prevention of endothelial dysfunction in a patient wherein the level of Pro-Adrenomedullin or a fragment thereof in a sample of bodily fluid obtained from said patient is above a threshold, as well as methods of therapy guidance or therapy stratification or therapy monitoring of a treatment of a patient with a DPP3 binder, the methods comprising: providing a sample of bodily fluid of said patient; determining the level of Pro-Adrenomedullin or a fragment thereof in said sample; and comparing said level of Pro-Adrenomedullin or a fragment thereof to a threshold; wherein the level of Pro-Adrenomedullin or a fragment thereof in said sample being above said threshold is indicative that said patient requires treatment with a DPP3 binder, or wherein if said level of Pro-Adrenomedullin or a fragment thereof in said sample is above said threshold, said patient is treated with a DPP3 binder.

The invention belongs to the technical field of biological agents, and particularly relates to application of Roseburia inulinivorans in preparation of a medicine for treating and / or preventing enteritis. The invention finds that the intestinal bacteria Roseburia inulinivorans can improve ulcerative colitis by adjusting the steady state of microorganisms, protecting the integrity of intestinal barriers and maintaining the steady state of immunity. According to the application, the curative effect of Roseburia inulinivorans on colitis is comprehensively evaluated, and the Roseburia inulinivorans has the functions of resisting inflammation, recovering immune balance, resisting oxidative stress, resisting pyroptosis, regulating bile acid metabolism, relieving endothelial dysfunction and intestinal ecological dysfunction and the like, and particularly, the Roseburia inulinivorans can achieve the treatment effect the same as that of a clinical conventional medicine mesalazine. And meanwhile, the Roseburia inulinivorans has no side effects, so that the Roseburia inulinivorans have no side effects. Therefore, the Roseburia inulinivorans is very likely to become a good candidate drug for improving the ulcerative colitis.

The invention discloses a multifunctional intravascular stent for diabetics and a preparation method of the multifunctional intravascular stent, and relates to the technical field of cardiovascular interventional therapy instruments. The polycitrate is used as a carrier on the surface of the intravascular stent body to form the drug-loaded slow-release coating, and the drug-loaded slow-release coating has high antioxidant content, can provide oxidative stress attenuation continuously for a long time, provides a good microenvironment for cell tissue recovery, and promotes regeneration and repair of blood vessels. The biological immunosuppressor and the diabetes specific drug are loaded in the drug-loaded slow-release coating, the biological immunosuppressor is a drug having an excellent effect on common patients, the diabetes specific drug is a drug having a specific effect on diabetic patients, and the two drugs have a synergistic effect, so that the effect of treating diabetes is achieved; the coating on the surface of the intravascular stent has the effects of resisting inflammation, improving endothelial dysfunction and inhibiting proliferation and migration of smooth muscle cells aiming at diabetic patients so as to promote regeneration and repair of diseased blood vessels of the diabetic patients.

Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction.

The invention belongs to the technical field of disease treatment, and particularly relates to a composition for regulating blood sugar and microvascular homeostasis and a preparation method thereof. The composition for regulating the blood sugar and the microvascular homeostasis is prepared from the following components in parts by mass: 380 to 520 parts of peony seed oil, 260 to 440 parts of dihydromyricetin and 0.025 to 0.062 part of chromium picolinate. The composition for regulating blood sugar and microvascular homeostasis can be used for protecting microvessels, regulating blood sugar, improving microcirculation of the whole body and preventing diabetic complications, and is suitable for preventing and treating diseases such as hyperglycemia, hyperlipidemia and glycolipid metabolism syndrome. Experiments on vascular endothelial dysfunction of obese rats show that the composition disclosed by the invention can be used for remarkably improving microvascular endothelial functions of the obese rats and effectively delaying rise of arterial blood pressure. Experiments on mouse diabetic cardiomyopathy find that the composition has a definite myocardial protection effect on DCM mice.

The present invention relates to pharmaceutical, dietary and / or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H2S) so to feed the redox buffer capacity and to boost the natural ability to compensate both oxidative and reductive stress.The invention further relates to the use of the aforementioned compositions to correct signs of metabolic derangements such as: oxy-redox imbalances including reductive stress, mitochondrial dysfunction and bioenergetics, insulin resistance, endothelial dysfunction and hyperhomocysteinemia. Accordingly, the composition of the present invention can be used as a medicament for the treatment of hypertension, atherosclerosis and cardiovascular disease, erectile dysfunction, viral infections and inflammatory lung injuries, diabetes and PCOS, autoimmune diseases, neurodegeneration, repeated implantation failure and repeated miscarriage and infertility in both men and women.

The invention discloses a quercetin pill for reducing hypertension by improving the vascular endothelial function, and relates to the technical field of quercetin pharmaceutical preparations. Comprising quercetin, eucommia ulmoides extract, hydroxypropyl-beta-cyclodextrin and hydroxypropyl methylcellulose. The quercetin pill can be used for preparing medicines for preventing and / or treating vascular endothelial dysfunction related cardiovascular diseases, especially hypertension closely related to a vascular endothelial injury mechanism. Quercetin promotes synthesis and release of nitric oxide of vascular endothelial cells, and NO is a powerful vasodilator and can diffuse to vascular smooth muscle cells, activate guanylate cyclase and increase cyclic guanosine monophosphate in the cells, so that the vascular smooth muscles are relaxed, blood vessels are expanded, and the vascular endothelial function is improved. In addition, quercetin can inhibit expression of inflammatory adhesion molecules and recruitment of inflammatory cells, so that inflammatory response of vascular endothelium is relieved. The problem that the use of quercetin in the aspect of reducing hypertension is limited in the prior art is solved.

The present application is directed to a method for the prediction of a risk of side effects and / or prediction of the severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), and / or for assessing an effect of a treatment of side effects in a cancer patient that has been treated with immune effector cells in the frame of an IECT, the method comprising the steps of a) determining the level of at least one endothelial dysfunction biomarker in a sample of bodily fluid of said patient, and b) correlating said level of said at least one endothelial dysfunction biomarker in said sample to the risk of said side effects and / or the severity of said side effects in said patient and / or to the effect of said treatment of said side effects in said patient. Further aspects relate to corresponding methods stratification and medicaments for use in correponding treatment.

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None

The invention relates to a medicament and a method for treating or preventing vascular diseases. Specifically, the invention relates to a method for treating or preventing vascular endothelial dysfunction related diseases by down-regulating phosphodiesterase 4, and application of a phosphodiesterase 4 inhibitor in preparation of drugs for treating or preventing vascular endothelial dysfunction related diseases.

The invention belongs to the technical field of medical chemistry, and particularly relates to a preparation method and application of eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. According to the preparation method of the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester, provided by the invention, 2-(3-indolyl) ethanol and eicosapentaenoic acid are used as raw materials, and lipase is added to react and synthesize the eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester. The eicosapentaenoic acid-2-(1H-indole-3-yl) ethyl ester prepared by the preparation method disclosed by the invention has an excellent and comprehensive lipid-lowering effect, not only can effectively reduce the contents of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum, but also can effectively increase the level of high-density lipoprotein cholesterol. Meanwhile, the compound also has a strong direct blood vessel protection effect, can remarkably repair vascular endothelial dysfunction caused by high-fat diet and effectively recover endothelium-dependent vasodilatation capability, and is a safe and effective novel cardiovascular disease medicine.

This invention discloses the application of 4-octyl itaconic acid (4-OI) in the preparation of drugs to improve pulmonary arterial hypertension (PAH). In vivo experiments showed that 4-OI significantly reduced pulmonary vascular wall thickening and collagen deposition in a rat model of PAH, effectively improving PAH and vascular remodeling. In vitro experiments further revealed that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting the PERK-eIF2α pathway, thereby blocking SM22-dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transition (EndMT) processes, ultimately inhibiting vascular remodeling and exerting a therapeutic effect on PAH. This invention closely links the three key pathological processes of ERS, EndMT, and vascular remodeling, providing a new perspective for a deeper understanding of the relationship between oxidative stress, endothelial dysfunction, and vascular structural changes in PAH. It also lays a theoretical foundation for the development of precision drugs for the treatment of PAH and vascular remodeling, and has clinical translational value.

The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof.

The invention discloses application of L-(+)-ergothioneine in preparation of a medicine for improving vascular endothelial dysfunction of preeclampsia, and belongs to the technical field of biology. The invention discloses an application of L-(+)-ergothioneine in preparation of a medicine for improving preeclampsia vascular endothelial dysfunction. The preeclampsia vascular endothelial dysfunction is improved by adjusting an Nrf2-PPARgamma-sFlt-1 axis. After LPS modeling, the transfer amount of Nfr2 protein in a cell nucleus of a trophoblast cell is remarkably increased, and LET inhibits the transfer amount of the Nfr2 protein in the cell nucleus. LET can activate PPAR gamma so as to achieve the effect of improving the phenotype of trophoblast cell PE. After the LET treats the trophoblast cells, generated metabolites can promote growth and migration of endothelial cells.

This invention proposes compounds of formula IA, IB, IC, ID, IE, IF, IG, IH, or IJ for the treatment or prevention of the following vascular endothelial dysfunction or vascular leakage diseases:

The invention provides application of nesudil in preparation of a medicine for improving or treating diabetes-related corneal endothelial dysfunction, and particularly belongs to the technical field of medicine preparation. The invention provides an application of nesudil in preparation of a medicine for improving or treating corneal endothelial dysfunction related to diabetes mellitus. The medicine prepared from nesudil can improve the diabetes-related corneal endothelial dysfunction and realize the treatment of the diabetes-related corneal endothelial dysfunction.

The application belongs to the technical field of medicine, and particularly relates to a blood vessel targeting anti-aging oral composition and application thereof. In view of problems such as endothelial dysfunction, matrix sclerosis and accumulation of senescent cells caused by vascular aging, the composition comprises active ingredients: beetroot extract, fisetin, salvianolic acid B, panax notoginseng total saponins, cocoa flavanol, pterostilbene, procyanidin B2, luteolin, nicotinamide riboside and astaxanthin. The composition is prepared by a process of adsorbing astaxanthin on beetroot extract, mixing other active ingredients, fillers and glidants after fisetin and salvianolic acid B are prepared into a solid dispersion, and sequentially cooperating each module, so that the pulse wave transmission velocity can be significantly reduced and the skeletal muscle capillary density can be increased, and the composition is mainly used for preparing a medicine for improving vascular stiffness, promoting microcirculation and removing vascular senescent cells.

The application discloses an application of perirenal adipose tissue exosomes rich in miRNA-486 in inducing endothelial dysfunction, wherein the perirenal adipose tissue exosomes are derived from adipose tissue around mammalian kidneys, rich in micro miRNA-486, have a particle size of 30-150 nanometers, have surface markers CD63, CD81 and TSG101, and have an expression level of the miRNA-486 in the perirenal adipose tissue exosomes increased by 3-5 times relative to a normal control, so that the perirenal adipose tissue exosomes can transmit the miRNA-486 to cells when being taken by vascular endothelial cells, and induce abnormal functions of the endothelial cells. The application proves that the perirenal adipose tissue exosomes rich in miR-486 can be taken by vascular endothelial cells in a specific manner through in-vivo and in-vitro experiments.

The invention provides an application of a pigment epithelium-derived factor in the aspect of treating or relieving corneal endothelial dystrophy and corneal endothelial dysfunction, in particular to an application of the pigment epithelium-derived factor in preparation of drugs for treating or relieving corneal endothelial dystrophy and corneal endothelial dysfunction. The PEDF is used for treating Fuchs corneal endothelial dystrophy for the first time, and it is proved that the PEDF can effectively relieve corneal endothelial cell injury, remarkably promote corneal transparency and thickness recovery, relieve corneal edema and promote corneal endothelial cell density, morphological repair and functional reconstruction. The method has good social value, PEDF medicine treatment has the advantages of being sufficient in source, easy and convenient to operate, low in treatment cost, small in risk and the like, and the requirements of corneal transplantation surgery in clinic can be reduced.

The invention relates to SLC22A6-targeted polypeptide, antibody, composition and application thereof in treatment and diagnosis of atherosclerosis, and researches find that expression of SLC22A6 in atherosclerotic endothelial cells is up-regulated, and glycolysis and lactic acid accumulation are promoted to drive H3K9 lactylation and activate SCD1 expression so as to mediate endothelial dysfunction and disease progression. Based on this, the invention provides a polypeptide and a monoclonal antibody which can specifically bind and inhibit the function of SLC22A6, and a pharmaceutical composition containing the polypeptide and the monoclonal antibody can be used for preventing or treating atherosclerosis. Meanwhile, the invention further provides a diagnostic kit containing the SLC22A6 detection reagent and a drug screening method taking the SLC22A6 as a target spot, and a new tool and strategy are provided for accurate intervention of atherosclerosis.

The present application is directed to a method for the prediction of a risk of side effects and / or prediction of the severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), and / or for assessing an effect of a treatment of side effects in a cancer patient that has been treated with immune effector cells in the frame of an IECT, the method comprising the steps of a) determining the level of at least one endothelial dysfunction biomarker in a sample of bodily fluid of the patient, and b) correlating the level of the at least one endothelial dysfunction biomarker in the sample to the risk of the side effects and / or the severity of the side effects in the patient and / or to the effect of the treatment of the side effects in the patient. Further aspects relate to corresponding methods stratification and medicaments for use in corresponding treatment.